Behavioral Psychedelics: Integrating Mind and Behavior to Improve Health and Resilience.
behavioral health
chronic disease
guidelines
intervention
psychedelics
psychotherapy
resilience
treatment
Journal
Frontiers in psychiatry
ISSN: 1664-0640
Titre abrégé: Front Psychiatry
Pays: Switzerland
ID NLM: 101545006
Informations de publication
Date de publication:
2022
2022
Historique:
received:
24
11
2021
accepted:
03
02
2022
entrez:
1
4
2022
pubmed:
2
4
2022
medline:
2
4
2022
Statut:
epublish
Résumé
One of the most recent and potentially promising advancements in the health sciences has involved the attempted use of psychedelics for treating mental and behavioral health problems, such as anxiety, depression, posttraumatic stress disorder, and addiction. Despite surging scientific and public interest in this work, however, we presently have no standard of care or consensus regarding how best to combine psychotherapy and psychedelics or to assess effectiveness. We discuss these timely issues here through the lens of
Identifiants
pubmed: 35360129
doi: 10.3389/fpsyt.2022.821208
pmc: PMC8964031
doi:
Types de publication
Journal Article
Langues
eng
Pagination
821208Informations de copyright
Copyright © 2022 Neuhaus and Slavich.
Déclaration de conflit d'intérêts
EN is Senior Director of Psychology for atai Life Sciences, which produces psychedelic compounds. GS has consulted for atai Life Sciences.
Références
N Engl J Med. 2021 Apr 15;384(15):1402-1411
pubmed: 33852780
PLoS One. 2020 Oct 14;15(10):e0239997
pubmed: 33052965
JAMA Psychiatry. 2021 Feb 1;78(2):121-122
pubmed: 32725172
Pharmacol Ther. 2019 May;197:83-102
pubmed: 30521880
PLoS One. 2016 Apr 22;11(4):e0154387
pubmed: 27105432
Nat Med. 2021 Jun;27(6):1025-1033
pubmed: 33972795
Health Aff (Millwood). 2021 Jan;40(1):14-24
pubmed: 33326300
J Consult Clin Psychol. 1996 Apr;64(2):295-304
pubmed: 8871414